Arvinas
ARVN | NASDAQ
$6.77
-$0.05 (-0.73%)
At close: Nov 16, 2026, 4:00 PM ET
$6.77
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:43 PM ET
-0.73%
(1D)Rating
45
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #387/1021 (Top 38%)
Key Statistics
Market Data
Market Cap $443.33M
1D Range
6.70 6.89
52W Range
6.41 13.83
Valuation (TTM)
PE -37.61
PB 0.86
EV/EBITDA 4.96
Valuation (NTM)
Forward PE 42.62
Forward PEG 0.37
Price Target $12.00
Cash Flow
FCF Yield -36.0%
SBC Adj. FCF Yield -43.4%
SBC Impact -20.3%
Margins
Gross Margin 95.9%
Operating Margin -10.7%
FCF Margin -58.0%
Growth (CAGR)
Revenue 3Y | 5Y 19.9% |
65.0%
Dil EPS 3Y | 5Y 119.0% |
43.5%
FCF 3Y | 5Y 20.0% |
6.8%
Returns
ROA -1.6%
ROE -2.0%
ROIC -5.5%
Financial Health
Net Cash
$551M
Current Ratio 8.39
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. ...
Sector Healthcare
Industry Biotechnology
Employees 246
IPO Date Sep 27, 2018
Website www.arvinas.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 3, 2026
EPS
-$0.82
Beat +10.65%
YoY:
-70.83% REV
$500K
Miss -95.96%
YoY:
-98.81%Next Earnings
Feb 23, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
9
Consensus
Buy
Price Target
$12.00
Upside
+77.25%
Buy (7)
Hold (2)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ARVN